New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2013
08:05 EDTTEVATeva says additional QNASL data to be presented at AAAAI meeting
Teva Pharmaceutical announced that additional data analyzed from the Phase III clinical program for QNASL Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology in San Antonio, Texas on February 22-26. Data will be presented at the meeting regarding the efficacy of QNASL in treating the symptoms associated with seasonal and perennial allergic rhinitis, including the drug’s potential quality of life benefits and sleep quality improvement. Furthermore, the data also demonstrated nasal symptom relief in patients with SAR and PAR who received treatment with QNASL 24 hours after dosing. On March 23, 2012, the U.S. Food and Drug Administration approved QNASL. The product became available by prescription in April 2012.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
06:08 EDTTEVAPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 15, 2015
17:08 EDTTEVASoros Fund gives quarterly update on stakes
Subscribe for More Information
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.
May 14, 2015
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
May 13, 2015
08:02 EDTTEVAANI Pharmaceuticals acquires rights to testosterone gel 1%
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use